Lindsey Draper

Incredibly honored to join the PICI community as a Parker Scholar. Looking forward to working with the brightest minds to develop more effective TIL therapies for the patients who need them!

@TischCancer @JonAnker1 @IcahnMountSinai Congrats Jon!!

Jonathan Anker, MD, PhD, has been appointed as Instructor in Hem/Onc. He provides clinical services focused on genitourinary medical oncology and conducts research on tumor immunology and immunotherapy for urothelial cancer. @JonAnker1 @IcahnMountSinai scholars.mssm.edu/en/persons/jon…

Thank you for believing in me, supporting my vision across departments, and helping me to develop as physician-scientist. I can’t wait to see what we build at UCSF!

I’m deeply grateful to my mentors and sponsors who have made this possible, including @KoleRoybal , Edwin Alvarez, @drkomanduri , @LeemayChen1 , @Ashworth_SF , and many others.

I’m excited to share that I’ve officially joined the @UCSF faculty as an Adjunct Instructor in the @UCSFDOM ! I’ll be continuing my research in the @roybal_lab , using synthetic biology to develop more effective TIL therapies for ovarian cancer and other aggressive solid tumors.

Check out this postdoc opportunity in an awesome new lab at UCSF!

Online: Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic #colorectalcancer: a first-in-human, single-centre, phase 1 trial Paper online today, Emil Lou (@cancerassassin1) presenting at #AACR25 bit.ly/3Guqc3L

Extremely excited re: IMA203 - PRAME TCR T cells Ph 1 study published in @NatureMedicine! This is a transformative Rx in #melanoma for HLA-A201+ & PD1 refractory pts. Compared to TIL, easier to make, less toxic & so far ~2x response rate in heavily pre-Rx. nature.com/articles/s4159…

At a time when public funding for research is under pressure, PICI is doubling down on our founding vision by championing bold science and accelerating the most promising breakthroughs in cancer immunotherapy. With the appointment of @DrKarenKnudsen as our new CEO, PICI is entering our next chapter—not just continuing the work, but scaling it. More in @Forbes: forbes.com/sites/alexknap…

@majo__duran @srikosuri So sorry to hear this news. I will ask my peds heme/onc colleagues who they recommend.

@srikosuri Sri, I’m incredibly sorry. I’ve had some truly pure conversations with her that I hold close to my heart. @Lindsey__Draper can you please do your magic here? 🙏🏼

It’s been a tough few weeks. My 10yo daughter was diagnosed with a very rare, aggressive cancer called interdigitating dendritic cell sarcoma (IDCS). I’m reaching out to identify clinicians/patients who have encountered pediatric IDCS, indeterminate dendritic cell histiocytosis or other (non-LCH) histiocytic sarcomas cases. I'm trying to understand non-surgical chemo and targeted therapy options, new pathology markers to better diagnose subtypes/treatments, and any data on progression in pediatric patients. Please feel free to share – I’m trying to cast a wide net due to the rarity of this condition and how little is known. People can contact me directly at my first name (as written in my profile) at octant.bio.

@RahulBanerjeeMD @NEJM @MScordoMD @szusmani @MSKCancerCenter The future is genome editing for targeted integration!

1/ Sobering but important work in @NEJM by @MScordoMD @szusmani et al: fatal case of enteric T-cell lymphoma following cilta-cel (#MMsm CAR-T) CAR integration into the TP53 locus. One of few papers that informs clinical discussions the moment it comes out. My two takeaways:

@DrBetofMDPhD @StanfordCancer @SCIDirector @HwakeleeMD Congrats @DrBetofMDPhD !!! 🎉

Another landmark day for solid tumor cell therapy at @StanfordCancer with our first infusion of FDA approved afami-cel (Tecelra), an engineered TCR T cell therapy for synovial #sarcoma. We are thrilled to make this available to our patients!!

Apply here: aprecruit.ucsf.edu/JPF05147 Read more about what we do here: roybal-lab.org

🔬We’re hiring!🧬Passionate about #cellengineering? The @roybal_lab at @UCSF is #hiring a technician to help unlock the potential of #TILtherapy with #synbio! Join our team and revolutionize #celltherapy for the patients who need it. DM for info and please RT!

Such an important advancement for HLA-restricted therapies!

Excited to share our recent manuscript out at @Nature . @piraner and @majo__duran from @roybal_lab and @Mohamad_Abedi and @AdamChazin in David Baker's lab engineered synthetic receptors that sense natural and designer soluble cues. nature.com/articles/s4158…

I’m excited to share how a modular synthetic receptor called SNIPR opens new possibilities for immunotherapy by sensing both tumor-secreted factors and synthetic computationally designed soluble proteins: nature.com/articles/s4158….

@majo__duran 👏🏻👏🏻Congrats Majo!!! You’re unstoppable!!👏🏻👏🏻

Wow — MIT just awarded me the Presidential Graduate Fellowship for the next few years!! 🏅 Honored and thankful for the chance to push the limits of synthetic immunology from here!! Pd: if you’re also thinking about this field, let’s grab coffee!

TCR cell therapies vanquish solid tumors — finally nature.com/articles/s4158…